Its success reflects a rare alignment of properties: an exceptionally long half-life (168 h), high potency, wide therapeutic window, and time-integrated pharmacodynamics that accommodate low and variable absorption
Availability Issues: While the FDA has declared that the shortage is over, sporadic supply issues may still occur in certain areas due to high demand
This led to the development of higher-dose versions of GLP-1 drugs specifically for obesity: Saxenda was approved for weight loss in 2014 and then Wegovy was approved in 2021, demonstrating even more dramatic weight loss results
It's important not to inject earlier or change your dosing schedule unless advised by your prescribing clinician
However, while many studies have heralded the drugs benefits, particularly for metabolic issues linked to diabetes, many researchers have cautioned that there are potentially serious health risks as well, such as stomach paralysis and intestinal blockages
83 (6): 13409 Elanchezhian R, Ramesh E, Sakthivel M, et al